Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

AVANDARYL

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

Standard Dose
2MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary

Approval overview AVANDARYL is listed in Drugs@FDA under application 021700 (NDA).

Review priority: N/A Marketing status: Discontinued Active ingredient GLIMEPIRIDE; ROSIGLITAZONE MALEATE Form and strength TABLET;ORAL - 2MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SB PHARMCO Submission history Latest submission status date: 2015-12-16 00:00:00.

Structured Monograph

Clinical summary

Approval overview AVANDARYL is listed in Drugs@FDA under application 021700 (NDA). Review priority: N/A Marketing status: Discontinued Active ingredient GLIMEPIRIDE; ROSIGLITAZONE MALEATE Form and strength TABLET;ORAL - 2MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor SB PHARMCO Submission history Latest submission status date: 2015-12-16 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.